Analysts’ Recent Ratings Changes for Y-mAbs Therapeutics (YMAB)

Y-mAbs Therapeutics (NASDAQ: YMAB) recently received a number of ratings updates from brokerages and research firms:

• 3/5/2025 – Y-mAbs Therapeutics had its price target lowered by analysts at Morgan Stanley from $11.00 to $7.00. They now have an “underweight” rating on the stock.
• 3/5/2025 – Y-mAbs Therapeutics had its price target lowered by analysts at Bank of America Co. from $14.00 to $12.00. They now have a “neutral” rating on the stock.
• 3/5/2025 – Y-mAbs Therapeutics had its price target lowered by analysts at Truist Financial Co. from $21.00 to $18.00. They now have a “buy” rating on the stock.
• 3/3/2025 – Y-mAbs Therapeutics had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $23.00 price target on the stock.

Y-mAbs Therapeutics Stock Performance

YMAB traded up $0.27 during trading on Wednesday, reaching $4.81. The company had a trading volume of 21,689 shares, compared to its average volume of 327,790. The firm’s 50-day simple moving average is $5.85 and its 200 day simple moving average is $9.97. The company has a market cap of $217.27 million, a price-to-earnings ratio of -8.90 and a beta of 0.65. Y-mAbs Therapeutics, Inc. has a 12-month low of $4.25 and a 12-month high of $17.78.

Y-mAbs Therapeutics (NASDAQ:YMAB) last issued its quarterly earnings results on Tuesday, March 4th. The company reported ($0.15) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.02). The company had revenue of $26.50 million during the quarter, compared to analysts’ expectations of $26.70 million. Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. During the same period in the prior year, the business posted ($0.02) EPS. On average, sell-side analysts expect that Y-mAbs Therapeutics, Inc. will post -0.65 EPS for the current year.

Insider Buying and Selling

In other Y-mAbs Therapeutics news, insider Thomas Gad sold 10,810 shares of the firm’s stock in a transaction dated Friday, March 7th. The stock was sold at an average price of $5.23, for a total transaction of $56,536.30. Following the completion of the sale, the insider now directly owns 202,721 shares in the company, valued at approximately $1,060,230.83. This trade represents a 5.06 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 22.50% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Y-mAbs Therapeutics

Institutional investors have recently bought and sold shares of the business. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in shares of Y-mAbs Therapeutics during the 3rd quarter valued at about $44,000. KLP Kapitalforvaltning AS bought a new position in Y-mAbs Therapeutics in the 4th quarter worth approximately $46,000. Intech Investment Management LLC bought a new position in Y-mAbs Therapeutics in the 3rd quarter worth approximately $133,000. ProShare Advisors LLC bought a new position in Y-mAbs Therapeutics in the 4th quarter worth approximately $99,000. Finally, Empire Financial Management Company LLC bought a new position in Y-mAbs Therapeutics in the 3rd quarter worth approximately $210,000. 70.85% of the stock is currently owned by institutional investors and hedge funds.

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.